[Betablocker vs placebo in vasomotor headache. A double-blind crossover study].
Vasomotor headaches are commonly, especially in the international literature, classified under ordinary migraine. Since beta-blockers seem to be the drug of choice in the prevention of migraine, 30 patients were given placebo and three times 40 mg propranolol in a double-blind cross-over trial. Among 24 fully assessable sets of tests only four showed a decrease in the frequency of headaches by more than 50%. In three patients the frequency actually increased over the placebo effect.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D002986:Clinical Trials as Topic; D003027:Cluster Headache / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011433:Propranolol / Q000627:therapeutic use; D012107:Research Design; D014653:Vascular Headaches / Q000188:drug therapy*
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D011433:Propranolol
Betablocker vs Placebo bei vasomotorischem Kopfschmerz. Eine doppelblinde Cross-over-Studie.